For the first time, Stanford University, under the auspices of its Biodesign program, will sponsor a hands-on workshop for entrepreneurs in the medical device sectors. START-UP assembled a group of industry leaders who will be among the participating faculty, including David Douglass and John Maroney of Delphi Ventures, Richard Ferrari and Jay Watkins of De Novo Ventures, Wilson Sonsini's Casey McGlynn, and Paul Yock, MD, of Stanford's department of bioengineering, to discuss the do's and don'ts of early-stage entrepreneurship.
By Stephen Levin
Current business school curriculums are replete with
entrepreneurship programs for MBA candidates, and senior corporate
officers can have their pick of numerous executive education
programs designed to sharpen their entrepreneurial skills
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.
Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.
Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.
The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.
FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.
Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.
